Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors

Download All
Gain expert perspectives on the evolving role of HER3 in EGFR-mutated advanced NSCLC including the role of HER3-targeted therapies in the setting of EGFR TKI resistance, with this educational program featuring a series of short interactive virtual presentations with downloadable slidesets and a multidisciplinary audio podcast.
person default
Elise Hitron, MSN, FNP-C
Frank Schneider, MD
person default
Conor Ernst Steuer, MD

Podcast

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.

person default Elise Hitron, MSN, FNP-C Frank Schneider, MD person default Conor Ernst Steuer, MD Released: January 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings